{"id":"W3023737799","doi":"10.1016/j.parkreldis.2020.04.012","title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study","year":2020,"lang":"en","type":"article","venue":"Parkinsonism & Related Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sanofi K.K.; Bayer Yakuhin; Novartis Pharma; Ono Pharmaceutical; Eisai Canada; Mitsubishi Tanabe Pharma Corporation; Kao Corporation; Otsuka Pharmaceutical; Daiwa Securities Health Foundation; Sanofi; Kyowa Hakko Kirin; Boston Scientific Japan; Eisai; Daiichi-Sankyo; Ohara Pharmaceuticals; Kissei; Mylan; Ehime University; Boehringer Ingelheim Japan; Nihon Pharmaceutical; Alexion Pharmaceuticals; Nihon Medi-Physics; Takeda Pharmaceutical Company; Daiichi Sankyo Company; Meiji Seika Pharma; Dainippon Sumitomo Pharma; Novartis Pharmaceuticals Corporation; Kagoshima University; Medtronic; Asahi Kasei Pharma Corporation","keywords":"Parkinson's disease; Placebo; Double blind; Medicine; Disease; Physical therapy; Internal medicine; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005229202,0.0008209228,0.001999968,0.0003068535,0.0004840344,0.00006002851,0.0002482114,0.0001513013,0.0001800199],"category_scores_gemma":[0.0003066717,0.0005929109,0.0004246126,0.0005172637,0.000189404,0.0001938678,0.00007989382,0.0002989903,0.00001925453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007032992,"about_ca_system_score_gemma":0.0002497622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001121572,"about_ca_topic_score_gemma":0.00002327032,"domain_scores_codex":[0.9958111,0.0003297301,0.0009899385,0.001347842,0.0008473535,0.0006740341],"domain_scores_gemma":[0.9967186,0.0004722362,0.000493139,0.0006519918,0.0002221095,0.001441965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9218323,0.018231,0.002321944,0.00004894422,0.002900564,0.00005146006,0.002699529,0.0001956793,0.00001896757,0.0002057675,0.0001073828,0.05138646],"study_design_scores_gemma":[0.93116,0.02825932,0.001991663,0.0001563893,0.002305252,0.000002081013,0.000455232,0.001198954,0.00005662385,0.0002240996,0.03360422,0.0005861919],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696836,0.001068602,0.0003104765,0.001215797,0.0001285585,0.02654658,0.0001854046,0.0001827428,0.0006781984],"genre_scores_gemma":[0.994265,0.0007711095,0.0003418256,0.0008353938,0.00005155154,0.003025139,0.0003971964,0.0001489956,0.0001638073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05080027,"threshold_uncertainty_score":0.9996522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01491475238957364,"score_gpt":0.2872012289221813,"score_spread":0.2722864765326076,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}